The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
CIBINQO (Pfizer Australia Pty Ltd)
Product name
CIBINQO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
254 (255 working days)
Active ingredients
abrocitinib
Registration type
NCE/NBE
Indication
CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. CIBINQO can be used with or without medicated topical therapies for atopic dermatitis.